Psoriasis is an immune-mediated highly
heterogeneous skin disease
in which genetic as well as environmental factors play important roles.
In spite of the local manifestations of the disease, psoriasis may
progress to affect organs deeper than the skin. These effects are
documented by epidemiological studies, but they are not yet mechanistically
understood. In order to provide insight into the systemic effects
of psoriasis, we performed a nontargeted high-resolution LC–MS
metabolomics analysis to measure plasma metabolites from individuals
with mild or severe psoriasis as well as healthy controls. Additionally,
the effects of the anti-TNFα drug Etanercept on metabolic profiles
were investigated in patients with severe psoriasis. Our analyses
identified significant psoriasis-associated perturbations in three
metabolic pathways: (1) arginine and proline, (2) glycine, serine
and threonine, and (3) alanine, aspartate, and glutamate. Etanercept
treatment reversed the majority of psoriasis-associated trends in
circulating metabolites, shifting the metabolic phenotypes of severe
psoriasis toward that of healthy controls. Circulating metabolite
levels pre- and post-Etanercept treatment correlated with psoriasis
area and severity index (PASI) clinical scoring (R2 = 0.80; p < 0.0001). Although the
responsible mechanism(s) are unclear, these results suggest that psoriasis
severity-associated metabolic perturbations may stem from increased
demand for collagen synthesis and keratinocyte hyperproliferation
or potentially the incidence of cachexia. Data suggest that levels
of circulating amino acids are useful for monitoring both the severity
of disease as well as therapeutic response to anti-TNFα treatment.